Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-04-07

Clinical Trial Update: A Study of Nilotinib Versus Imatinib in GIST Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing nilotinib to imatinib in gastrointestinal stromal tumor has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Imatinib (imatinib)
  • Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Gastrointestinal Stromal Tumor (GIST) | Phase 3 | Status: COMPLETED | Results posted: 2016-04-07